Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance

By sjmartinez • September 22, 2022

Charles-Schoeman C, Buch MH, Dougados M, Bhatt DL, Giles JT, Ytterberg SR, Koch GG, Vranic I, Wu J, Wang C, Kwok K, Menon S, Rivas JL, Yndestad A, Connell CA, Szekanecz Z. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance. Ann Rheum Dis. 2022 Sep 22:annrheumdis-2022-222259. doi: 10.1136/ard-2022-222259. Epub ahead of print. PMID: 36137735.

Tags: Antirheumatic Agents, Arthritis, cardiovascular diseases, Publications, Rheumatoid, Rheumatology, Therapeutics

Tiragolumab Plus Atezolizumab and Chemotherapy for Advanced Nonsquamous Non-Small Cell Lung Cancer: The Phase 3 SKYSCRAPER-06 Randomized Clinical Trial

Socinski MA, Stahel R, Lee DH, Cappuzzo F, Nishio M, Lovly CM, Ozyilkan O, Li Q, Johnson M, Garon EB, Kilickap S, Ferreira da Silva[...]

Discrepancy between reference phenotypic and genotypic detection of cphA metallo-β-lactamase in Aeromonas spp

von Bredow B, Trejo M, Ward KW, Trieu KP, Santellan CA, Garner OB, Yang S, Chandrasekaran S. Discrepancy between reference phenotypic and genotypic detection of cphA metallo-β-lactamase[...]

Plaque, P-Values, and Presentation Bias: Four Limitations of the EKSTROM Trial

Budoff MJ, Verghese D, Kinninger A, Lakshmanan S. Plaque, P-Values, and Presentation Bias: Four Limitations of the EKSTROM Trial. Eur Heart J Cardiovasc Imaging. 2026[...]